Neuro Athletics is a twice-weekly newsletter designed specifically for high-performing men and women who want science-backed strategies to optimize brain health, performance, and longevity. If you’re not already subscribed, join 69,000+ people who receive actionable insights directly in their inbox each week.
If you’ve spent more than fifteen minutes on fitness TikTok, you’ve heard the whispers. BPC-157—the “body protection compound” that supposedly heals tendons like you’re Wolverine, fixes your gut like magic, and regenerates tissue faster than your ex moves on. Biohackers inject it into their shoulders. Longevity clinics charge premium prices to administer it. Reddit threads read like religious testimony.
There’s just one small problem: not a single randomized controlled trial has ever been completed in humans.
Let that sink in. This peptide has been injected into thousands of people, sold by hundreds of clinics, discussed in millions of social media posts—and the entire evidence base for its healing properties comes from rodents. Specifically, rats.
Even more specifically, rats studied predominantly by one research group in Zagreb, Croatia.
I just spent weeks tearing apart injectable peptides with zero human data. But topical peptides? Completely different science.
Cellure was built by a founder who needed real skin repair after a botched skin booster and four rounds of hyaluronidase. When nothing worked, she went deep into regenerative actives.
The Complete Skin Repair Kit is a trio of serums — copper peptides, PDRN, tranexamic acid, neuromodulating peptides, hyaluronic acid — formulated for sensitive skin that can’t handle aggressive actives.
Smooth finish. Subtle lift. Soft, glassy glow. No grease.
Use code NEURO for 20% off.
GET 20% OFF
The Numbers Don’t Lie
A 2025 systematic review published in HSS Journal did what science is supposed to do: they screened the entire published literature on BPC-157 from an orthopaedic sports medicine perspective. They started with 544 articles spanning from 1993 to 2024.
The final count? 36 studies made the cut. 35 were preclinical (animal studies). Exactly one tested the peptide in humans.
That single human study? A retrospective case series of 12 people with chronic knee pain who received intra-articular BPC-157 injections. No control group. No blinding. No validated outcome measures. Seven out of twelve reported relief lasting more than six months—which tells us approximately nothing, given that knee pain often improves with time, attention, and the powerful expectation that comes with paying for a novel injection.
That’s not evidence. That’s expensive placebo with extra steps.
Injectable vs. Topical: Two Completely Different Conversations
I need to be really clear about something, because I know some of you are going to read the word “peptide” on a skincare label and think — didn’t she just spend three weeks telling us peptides are unregulated garbage?
Yes. And I meant it. But context matters.
When I went after BPC-157, I was talking about a specific molecule, sold through gray market suppliers and unregulated compounding pharmacies, that people are injecting subcutaneously — into their muscle tissue, into their joints — based on animal data from a single research group in Zagreb. No completed randomized controlled human trial. No Phase II. No Phase III. The FDA placed it in Category 2, which means it presents significant safety concerns including immunogenicity — the risk that your own immune system mounts a response against it. Third-party testing has found heavy metal contamination in commercially available vials. That is what I was talking about.
Topical peptide skincare is not that.
It’s not even the same conversation.
A topical peptide serum sits on your skin. It doesn’t bypass your gut. It doesn’t enter systemic circulation. It doesn’t carry immunogenicity risk. It doesn’t require a sterile compounding environment. And critically — some topical peptides actually have human clinical trial data.
Copper peptides — specifically GHK-Cu — are among the most studied peptides in dermatology. In a clinical trial of 71 women with mild to advanced photoaging, a GHK-Cu facial cream applied daily for twelve weeks significantly increased skin density and thickness while reducing fine lines, wrinkles, and laxity. A separate human trial found that topical GHK-Cu produced collagen increases in 70% of the women treated — outperforming both vitamin C and retinoic acid. That’s not a rat study. That’s not an in vitro petri dish. That’s human skin, measured, published, and peer-reviewed.
So when someone says “peptides don’t work” — ask them which one. Ask them the delivery route. Ask them for the trial data. Because saying “peptides are all the same” is like saying “all medications are the same” because they both come in a bottle.
The molecule matters. The delivery matters. The evidence matters.
Rats Are Not Small Humans
The animal data is impressive—I’ll give you that. BPC-157 accelerates Achilles tendon healing in rats. It helps with muscle crush injuries in rats. It protects gastric mucosa in rats. It apparently does everything short of filing their taxes.
But here’s the inconvenient truth that the peptide salesmen won’t mention: the history of medicine is littered with compounds that worked brilliantly in rodents and failed spectacularly in humans. Rat physiology isn’t human physiology. Their tendons heal differently. Their immune systems respond differently. Their metabolic pathways diverge from ours in ways that can make a “miracle compound” in one species become a dud—or worse, a danger—in another.
A 2025 review in Pharmaceuticals put it bluntly: “There are obvious differences between the physiologies of rodents and humans. Therefore, a still completely unknown mechanism of action, efficacy, and safety profile cannot be ignored.”
Translation: we don’t actually know what this stuff does in your body, because nobody has properly studied it in your body.
The FDA Saw the Writing on the Wall
In 2023, the U.S. Food and Drug Administration classified BPC-157 as a Category 2 bulk drug substance. In regulatory speak, this means: “significant safety concerns.” Compounding pharmacies can no longer legally produce it for human use.
Why? Two primary reasons:
First, immunogenicity. BPC-157 is a synthetic peptide, and when you inject synthetic peptides into your body, your immune system may decide they’re foreign invaders. The concern isn’t just that you’ll develop antibodies against the peptide itself—it’s that those antibodies might cross-react with your own endogenous proteins. Your immune system could start attacking tissues it was supposed to protect. This isn’t theoretical fear-mongering; it’s a well-documented risk with synthetic peptides that has ended pharmaceutical development programs.
Second, nobody knows the long-term safety profile. Zero completed Phase III trials. No systematic surveillance of adverse events. No pharmacovigilance data. As the systematic review noted: “No clinical safety data were found.”
When the FDA says “insufficient evidence,” they mean it—we literally do not have the data to know whether chronic BPC-157 use causes problems that emerge years down the road.
The Gray Market Horror Show
But wait—if compounding pharmacies can’t make it, where are people getting BPC-157? Welcome to the research chemical gray market, where you can buy injectable peptides with Bitcoin and a prayer.
The systematic review notes that “anywhere between 12% and 58% of ergo-nutritional supplements are contaminated with other, oftentimes unsafe, substances.” Research peptides operate with even less oversight than supplements. When you inject that vial of “BPC-157” you bought from an overseas website, you’re trusting an unregulated lab in an unregulated industry with no legal accountability for what they put in your body.
As one expert told NutraIngredients in December 2025: “It’s really a choose-your-own-adventure. It’s up to the chemical companies making these things to figure out quality control... It’s anybody’s guess what’s really happening with the quality control of these unregulated peptides.”
The products marketed as BPC-157 are, according to the systematic review, “unregulated for quality and safety.” You know, minor details.
The Pleiotropic Red Flag
There’s another reason to be skeptical that goes beyond missing human data: the sheer breadth of BPC-157’s claimed benefits. According to the literature, this single 15-amino-acid peptide heals tendons, repairs muscles, protects the gut, fixes the liver, recovers spinal cord injuries, treats retinal ischemia, counteracts drug toxicity, and regulates neurotransmitters.
In medicine, we have a saying: when something claims to do everything, it usually does nothing—or it’s overriding fundamental biological safety mechanisms. Drugs that promote healing and tissue regeneration often work by manipulating pathways like angiogenesis (blood vessel growth) and cell proliferation. These are the same pathways cancer cells exploit to grow and spread.
I’m not saying BPC-157 causes cancer. I’m saying we don’t know if it causes cancer, because no one has done the long-term studies to find out. A compound that claims to heal everything might heal nothing. Or it might heal something while quietly causing something else. The honest answer is: we don’t know.
Here’s to protecting your brain with evidence, not hype.
Louisa x